UroGen Pharma (NASDAQ:URGN - Get Free Report) is expected to release its earnings data before the market opens on Thursday, March 13th. Analysts expect UroGen Pharma to post earnings of ($0.69) per share for the quarter. Persons interested in registering for the company's earnings conference call can do so using this link.
UroGen Pharma Price Performance
Shares of NASDAQ URGN traded down $0.37 during trading on Friday, reaching $9.82. The company had a trading volume of 390,798 shares, compared to its average volume of 370,732. UroGen Pharma has a 52 week low of $9.03 and a 52 week high of $20.70. The stock has a market cap of $230.32 million, a PE ratio of -3.12 and a beta of 1.12. The company has a debt-to-equity ratio of 4.77, a quick ratio of 8.77 and a current ratio of 9.00. The business's 50 day moving average price is $10.45 and its 200-day moving average price is $11.78.
Analyst Upgrades and Downgrades
A number of brokerages have weighed in on URGN. D. Boral Capital reaffirmed a "buy" rating and issued a $25.00 target price on shares of UroGen Pharma in a research note on Tuesday, February 18th. HC Wainwright reissued a "buy" rating and set a $64.00 price target on shares of UroGen Pharma in a research note on Tuesday, February 25th. Finally, LADENBURG THALM/SH SH assumed coverage on shares of UroGen Pharma in a research note on Wednesday, February 19th. They set a "buy" rating and a $31.00 price target for the company. Five analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat, the company presently has a consensus rating of "Buy" and an average price target of $40.00.
View Our Latest Report on URGN
Insider Buying and Selling
In related news, General Counsel Jason Drew Smith sold 7,379 shares of the business's stock in a transaction that occurred on Friday, January 31st. The shares were sold at an average price of $11.14, for a total transaction of $82,202.06. Following the completion of the transaction, the general counsel now owns 26,468 shares in the company, valued at approximately $294,853.52. The trade was a 21.80 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Mark Schoenberg sold 4,551 shares of the business's stock in a transaction that occurred on Friday, January 31st. The shares were sold at an average price of $11.14, for a total transaction of $50,698.14. Following the transaction, the insider now owns 145,666 shares of the company's stock, valued at approximately $1,622,719.24. This represents a 3.03 % decrease in their position. The disclosure for this sale can be found here. 5.10% of the stock is currently owned by insiders.
UroGen Pharma Company Profile
(
Get Free Report)
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.
Further Reading
Before you consider UroGen Pharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and UroGen Pharma wasn't on the list.
While UroGen Pharma currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
